San Diego

Pharma

Sydnexis scoops $45M to treat short-sightedness in kids

Sydnexis will use the cash to wrap up a phase 3 clinical trial of a low-dose atropine eye drop candidate designed to have superior stability.
Nick Paul Taylor Aug 17, 2021 8:30am

Recro plots $50M deal to buy Irisys and take CDMO biz bi-coastal

Aug 16, 2021 12:01pm

U.K. manufacturer Abzena pumps $60M into San Diego plant

Oct 9, 2020 10:35am

Ajinomoto Althea expanding GMP production at CA facility

Sep 19, 2017 11:07am